Achondroplasia
Emerging Competitors in Achondroplasia Treatment: BioMarin’s Dominance Faces New Challenges
Achondroplasia, BioMarin, Voxzogo, BridgeBio, infigratinib, TransCon CNP, RBM-007, skeletal disorders, dwarfism, genetic bone disorders.
Ascendis Challenges BioMarin’s Dominance with Promising Achondroplasia Drug Data
Achondroplasia, Ascendis Pharma, BioMarin, TransCon CNP, VOXZOGO, Dwarfism Treatment
Sanofi Deprioritizes Four Assets, Including Mid-Stage Dwarfism Treatment
Sanofi, dwarfism, mid-stage treatment, asset deprioritization, rare disease, achondroplasia
BridgeBio’s Infigratinib Demonstrates Sustained Efficacy in Phase 2 Trial for Achondroplasia Treatment
BridgeBio, Infigratinib, Achondroplasia, Hypochondroplasia, Phase 2 Trial, Growth Disorder Treatment
Kyowa Kirin Partners with BridgeBio for Potential Achondroplasia Drug, Pays $100M in Pivotal Collaboration
Achondroplasia, infigratinib, BridgeBio, Kyowa, Kirin, Collaboration